News
Drug and biotech news
Last checked: Nov 20, 2026Source: BioPharma Dive, STAT (pharma), FDA press releases, FDA MedWatch, Drugs@FDA (new approvals), openFDA (Class I recalls)
4 stories
Tagged Cardiovascular and metabolic from the headline and teaser, so some stories may be missed or misfiled.
- FDA approvalDrugs@FDANov 13, 2026FDA new use approved: Myqorzo (Aficamten), Cytokinetics
Efficacy supplement 2. Orphan.
- FDA approvalDrugs@FDANov 9, 2026FDA novel drug approval: Sunharbo (Asundexian), Bayer Healthcare
To reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack Priority review.
- FDA approvalDrugs@FDAOct 23, 2026FDA new use approved: Awiqli Flextouch (Insulin Icodec), Novo Nordisk INC
Efficacy supplement 1. Priority review.
- FDA approvalDrugs@FDAOct 9, 2026FDA new use approved: Repatha (Evolocumab), Amgen INC
Efficacy supplement 47. Orphan.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.